Health care giant Johnson & Johnson's fourth-quarter profit dropped 28 percent as lower sales overseas, mainly because of unfavorable currency exchange rates, dragged down revenue for its consumer and medical device businesses. The maker of Tylenol, prescription drugs and joint replacements beat analysts' forecasts for adjusted net income but fell short of predictions for revenue.